HUYA Bioscience
HUYA Bioscience International is a private biopharmaceutical company that identifies, licenses, and globally develops clinical-stage drug compounds sourced from Chinese research institutions and pharmaceutical companies for Western markets, with a pipeline spanning oncology and cardiovascular indications.
- Company typePrivate
- Founded2007
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What HUYA Bioscience does
HUYA Bioscience International (operating as HUYABIO) is a private, for-profit biopharmaceutical company founded in 2004 and jointly headquartered in San Diego, California and Shanghai, China. The company operates a distinctive cross-border co-development model: it identifies and licenses promising pre-clinical and clinical-stage drug compounds from Chinese research institutions, universities, and pharmaceutical companies, then develops and commercializes them for ex-China (primarily US, EU, and Japan) markets. It maintains what it describes as the largest China-sourced compound portfolio covering all therapeutic areas — evaluating more than 600 candidates — and operates eight strategic offices across China alongside international offices in Japan, South Korea, Canada, and Ireland. Major Western pharmaceutical partners have included Organon, Abbott, Solvay, and Bristol Myers Squibb, while exclusive Chinese-origin licensing relationships anchor the upstream portfolio (e.g., chidamide from Shenzhen Chipscreen Biosciences and HBI-3000 from the Shanghai Institute of Materia Medica).
The company's lead asset is HBI-8000 (chidamide, branded Hiyasta® in Japan), an oral selective Class I histone deacetylase inhibitor approved as monotherapy for T-cell lymphoma in China (2014) and Japan (2021) and as combination therapy with an aromatase inhibitor for breast cancer in China (2019) and Taiwan (2023). The oncology pipeline extends into HBI-2376 (SHP2 inhibitor, FDA IND cleared, Phase 1), HBI-2438 (KRAS G12C inhibitor with blood-brain barrier penetration, Phase 1), HBI-2375 (first-in-class MLL1-WDR5 epigenetic inhibitor, ready for IND submission), and HBI-2448 (Wee1 inhibitor licensed from Shanghai Pharmaceuticals). The cardiovascular pipeline includes HBI-3000 (intravenous multi-ion channel blocker, completed Phase 1 and Stage A of Phase 2 in acute atrial fibrillation), HBI-3020 (oral follow-on for chronic AF maintenance), and HBI-3808 (cardiac regeneration therapy for post-myocardial infarction repair).
HUYABIO generates revenue through licensing fees, milestone payments, and royalties from co-development partnerships with major Western pharmaceutical companies, supplemented by product sales through regional distribution partners — most notably Meiji Seika Pharma as the exclusive distributor for Hiyasta® in Japan and other Asian countries. The company also receives clinical supply and development support from Bristol Myers Squibb for melanoma combination studies. Total disclosed funding across three rounds (2009, 2012, 2015) is approximately $60.6 million. The company is led by founder, CEO and Executive Chair Dr. Mireille Gillings, named Pharma Executive of the Year at the 2016 BioPharma Industry Awards.
HUYA Bioscience firmographics
Firmographics- Name
- HUYA Bioscience
- Legal name
- HUYA Bioscience International, LLC
- Website
- https://huyabio.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- HUYA Bioscience International is a private biopharmaceutical company that identifies, licenses, and globally develops clinical-stage drug compounds sourced from Chinese research institutions and pharmaceutical companies for Western markets, with a pipeline spanning oncology and cardiovascular indications.
- Ownership category
- akta.pro rank
HUYA Bioscience industry classification
Industry- Product category
- Biopharmaceutical Drug Development
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where HUYA Bioscience is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
HUYA Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Licensing and Co-development Agreements: HUYABIO identifies and licenses promising pre-clinical and clinical stage compounds from Chinese partners, then co-develops them with Western pharmaceutical companies. Revenue is generated through licensing fees, milestone payments, and royalties from commercialization. HUYABIO retains ex-China rights while Chinese partners retain China rights.
- Product Commercialization: Commercialization of approved products such as HBI-8000 (Hiyasta) in Japan and other markets. Revenue from product sales through distribution partners like Meiji Seika Pharma.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
HUYA Bioscience product offering
Product offeringCore offering
HUYABIO International identifies, licenses, and co-develops novel biopharmaceutical compounds originating from Chinese research institutions and pharmaceutical companies for global development and commercialization. The company's portfolio includes clinical-stage compounds in oncology (HBI-8000/Hiyasta, HBI-2376, HBI-2438, HBI-2375, HBI-2448) and cardiovascular (HBI-3000, HBI-3020, HBI-3808), with HBI-8000 approved and marketed in Japan for T-cell lymphomas under the brand Hiyasta.
Product overview
HUYABIO International operates as a biopharmaceutical company that identifies, licenses, and develops promising Chinese drug compounds for global markets. The company's core offering consists of a portfolio of clinical-stage compounds spanning two therapeutic areas: oncology (including HBI-8000/Hiyasta®, HBI-2376, HBI-2438, HBI-2375, and HBI-2448) and cardiovascular (HBI-3000, HBI-3020, and HBI-3808). HBI-8000 (Hiyasta®) is the lead commercial product, approved and marketed in Japan for T-cell lymphomas and in China/Taiwan for breast cancer. The remaining pipeline compounds are in various stages of clinical development from preclinical through Phase 2.
Differentiator
Problem solved
Functional benefit
Products and services
- HBI-8000 (Hiyasta) Selective Class I histone deacetylase (HDAC) inhibitor with immune modulatory properties; approved for treatment of T-cell lymphoma as monotherapy in China (2014) and Japan (2021), and in breast cancer as combination therapy with aromatase inhibitor in China (2019) and Taiwan (2023). Marketed in Japan under the brand Hiyasta.
- HBI-2376
Quantifiable outcome
- HBI-8000 approved and marketed in Japan for ATLL and PTCL
- +3 more outcomes
Companies that use HUYA Bioscience
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
HUYA Bioscience technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
HUYA Bioscience partnerships and signals
Strategic signalPartnerships
32 partnerships are on record, tiered minor and core.
- China Wuqing Development AreaminorStrategic collaboration focuses on promoting biomedical innovations from companies located in the Area. HUYA will have right of priority review to evaluate certain R&D projects and provide advice and consultation.
- TIPR-HUYA Advancing Innovative Medicines (Joint Venture)coreJoint venture between HUYA and Tianjin Institute of Pharmaceutical Research to develop medical technologies and therapies originating in both China and the western world for global markets. HUYA and TIPR share equally in decision-making regarding product development and commercialization, focusing initially on the fast-growing Chinese market.
- Changzhou Center for Biotech Development (CZCBD)minorPartnership focuses on advancing worldwide potential of innovations from bio-pharmaceutical companies located in Changzhou. HUYA will have right of priority review to evaluate certain R&D projects of local companies supported by CZCBD.
- Shanghai Zhangjiang Biotech Pharmaceutical BaseminorPartnership focuses on innovations from companies located in Zhangjiang Biotech Pharmaceutical Base. HUYA will have first opportunity to evaluate certain R&D projects conducted at the base and provide support and assistance.
- Tianjin Research Center of Basic Medical SciencesminorStrategic partnership focuses on innovations from this nonprofit research institution that could meet critical global pharmaceutical pipeline needs. HUYA will have first opportunity to evaluate certain R&D projects conducted at TJRCBMS.
- Fudan University - School of PharmacyminorPartnership with Prof. Deyong Ye's lab specializing in drug design and synthesis, including computer modeling of enzyme structures for SMS inhibitors targeting metabolic and cardiovascular diseases.
- Tianjin Institute of Pharmaceutical Research (TIPR)coreStrategic partnership combines both parties' strengths in promoting advancement of China's drug innovations. HUYA will have first opportunity to evaluate certain R&D projects conducted at TIPR and help globalize select programs.
- Shenzhen Polytechnic - School of Applied Chemistry and BiotechnologyminorPartnership provides HUYA with access to and first review of certain novel therapeutic candidates owned or controlled by the school. School gains access to HUYA's expertise in drug development and global network of pharmaceutical partners.
- Tianjin International Joint Academy of Biotechnology and Medicine (TJAB)minorAlliance will unite strength and resources of both parties to accelerate development of China's biomedical innovation and industrialization. HUYA will have first opportunity to provide assistance in evaluating R&D projects conducted by enterprises residing in TJAB.
- Zhejiang Chinese Medical University - Life Science CollegeminorCollaboration agreement will accelerate global drug development of China's novel Traditional Chinese Medicines (TCM). HBI-3000 was originally derived from a TCM.
- Liaoning (Benxi) Bio-Pharmaceutical Industry BaseminorCollaboration agreement combines both parties' strength in aiding advancement of China's drug innovation platform. HUYA will have first opportunity to provide assistance in evaluating R&D projects conducted by pharmaceutical enterprises residing in the base.
- Wuhan National Bio-industry Base (Biolake)minorStrategic alliance expected to combine both parties' resources to accelerate development of pharmaceutical discoveries from China. HUYA will have first opportunity to provide assistance in evaluating R&D projects conducted by pharmaceutical enterprises residing in Biolake.
- QuintilescorePartnership for Phase I development of HBI-8000. HUYA and Quintiles co-develop the new cancer drug sourced in China by HUYA. HBI-8000 entered Phase I clinical trial in the US under an IND application with the FDA.
- Sun Yat-sen University - School of Pharmaceutical SciencesminorPartnership expands HUYA's foothold in Southern China. Agreement provides HUYA with access to and first review of certain novel therapeutic candidates owned or controlled by SYSU's School of Pharmaceutical Sciences.
- China Medical City (Taizhou National Medical Hi-tech Development Zone)minorAlliance combines both parties' strengths in pharmaceutical product R&D and commercialization. HUYA will have first opportunity to provide assistance in evaluating R&D projects conducted by pharmaceutical companies residing in CMC.
- Beijing University of Chinese Medicine - School of Chinese Materia MedicaminorPartnership provides HUYA with access to and first review of certain novel therapeutic candidates owned or controlled by the school. HBI-3000, HUYA's anti-arrhythmic compound, was originally derived from a Traditional Chinese Medicine.
- Ocean University of China - School of Medicine and PharmacyminorStrategic partnership provides HUYA with rights of first review and negotiation relating to certain novel therapeutic and diagnostic product candidates owned or controlled by the University. Ocean University gains access to HUYA's global network of pharmaceutical partners and expertise in pre-clinical and clinical development.
- Solvay PharmaceuticalscoreSolvay Pharmaceuticals signed agreement to access HUYA's comprehensive Chinese molecule portfolio, focusing specifically on compounds in the cardiovascular area. Partnership helps Solvay speed up early discovery activities and increase chances for developing innovative new therapies.
- AbbottcoreAbbott gained access to HUYA's Chinese bioscience network to identify and pursue proprietary preclinical and clinical drug candidates originating in China. HUYA is currently evaluating and following the progress of more than 600 lead, preclinical and clinical drug candidates.
- Beijing Institute of Materia Medica (BIMM)corePartnership agreement grants HUYA opportunity to collaborate with BIMM on pre-clinical safety and efficacy, and clinical trial protocols. Also provides HUYA with right of first review and negotiation for licensing and development of certain new compounds owned or controlled by BIMM in cardiology, endocrinology, oncology, immunology, hematology, neuroscience and anti-infectives.
- Schering-Plough CorporationcoreSchering-Plough selected HUYA to identify and present proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in China on an exclusive basis.
- Shanghai Institute of Materia Medica (SIMM)coreHUYA licensed novel clinical stage anti-arrhythmic compound HBI-3000 (sulcardine) from SIMM, Chinese Academy of Sciences. The compound exhibits unique profile of myocardial ion channel regulation compared to approved US and European anti-arrhythmic therapeutics.
- Shenzhen Chipscreen Biosciences Ltd.coreHUYA exclusively licensed worldwide rights outside China to the cancer compound chidamide (HBI-8000) from Chipscreen. HUYA co-develops chidamide with Chipscreen through Phase I clinical trials in China.
- Organon (Akzo Nobel)coreOrganon signed collaboration agreement with HUYA to search for new proprietary biopharmaceuticals or pharmaceutical compounds. As part of the collaboration, Organon acquired an equity interest in HUYA. HUYA supports Organon in sourcing and development of pharmaceutical or biopharmaceutical compounds in three specific therapeutic areas.
- Meiji Seika PharmacoreMeiji Seika Pharma appointed as exclusive distributor for HBI-8000 in Japan and other Asian countries.
- Bristol Myers SquibbcoreGlobal clinical trial collaboration in melanoma. BMS is responsible for supply of Opdivo (nivolumab) for the trial, which is sponsored by HUYABIO.
- Shanghai Jemincare PharmaceuticalminorExclusive license of KRAS inhibitor from Shanghai Jemincare Pharmaceutical.
- Shanghai PharmaceuticalsminorExclusive license of Wee1 inhibitor from Shanghai Pharmaceuticals.
- Korea Drug Development FundminorStrategic alliance with the Korea Drug Development Fund for drug development.
- Suzhou BioTOPminorStrategic partnership with Suzhou BioTOP for development support.
- CAS Innovation and Investment CompanyminorStrategic collaboration with CAS Innovation and Investment Company.
- TechCode Gu'an Lifesciences ParkminorStrategic collaboration with TechCode Gu'an Lifesciences Park.
Scale indicators6 records
Recent moves9 records
Expansion highlights5 records
HUYA Bioscience competitors and assessment
Company assessmentDirect peers
- Hutchmed (Chi-Med): Hutchmed is a China-headquartered biopharma that discovers and develops novel oncology and immunology therapies for global markets — directly comparable to HUYABIO's China-to-global drug development model, with a similarly oncology-focused pipeline and US/EU/China commercialization footprint.
- BeiGene: BeiGene is a global oncology-focused biopharma built on China-originated assets (e.g., Brukinsa, tislelizumab) with deep China roots and a global commercial organization — closely comparable to HUYABIO in therapeutic focus and China-originating model, though at a much larger scale.
- Zai Lab: Zai Lab in-licenses and develops innovative drugs for China and global markets, including oncology assets. Comparable to HUYABIO in business model (licensing/co-development with global pharma) and therapeutic focus, though Zai Lab primarily targets the China market with global ambitions.
- Everest Medicines: Everest Medicines in-licenses and develops innovative therapies for the China and Asia-Pacific markets with a focus on anti-infectives and oncology. Similar to HUYABIO's licensing-driven, China-rooted development model with global aspirations.
- LianBio: LianBio was built explicitly as a bridge between China biopharma innovation and global development, in-licensing assets for China and US trials. Directly comparable to HUYABIO's China-to-global co-development model and therapeutic focus on serious diseases.
- Cstone Pharmaceuticals: CStone Pharmaceuticals is a China-based biopharma developing and commercializing immuno-oncology and precision medicines with global reach (notably through partnerships with Bayer and others). Comparable to HUYABIO in therapeutic focus (oncology), China origins, and licensing/co-development strategy.
- Antengene: Antengene develops and commercializes novel hematology and oncology therapies with operations in China, US, and Asia-Pacific. Comparable to HUYABIO in China-originating oncology pipeline and cross-border development model.
- I-Mab Biopharma: I-Mab is a China-US clinical-stage biopharma focused on immuno-oncology, with assets developed in China and tested globally. Similar to HUYABIO in China-originating biopharma innovation and US clinical presence, though I-Mab emphasizes biologics.
Emerging players
- BridgeBio Pharma: BridgeBio operates a hub-and-spoke model developing multiple genetically targeted therapies, similar in spirit to HUYABIO's portfolio approach of advancing multiple compounds in parallel, though BridgeBio focuses on US/European rare disease assets rather than Chinese sourcing.
- Roivant Sciences: Roivant operates a multi-asset "Vant" model that in-licenses and develops multiple therapeutic programs across subsidiaries — structurally comparable to HUYABIO's portfolio approach of sourcing and advancing multiple Chinese compounds, though with a different therapeutic and geographic focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
HUYA Bioscience social profiles
Digital presenceHUYA Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
HUYA Bioscience leadership team
Management profileNumber of profiles
Profiles14 records
HUYA Bioscience subsidiaries and ownership
Company hierarchySubsidiaries1 record
HUYA Bioscience funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HUYA Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HUYA Bioscience
What does HUYA Bioscience do?
HUYABIO International identifies, licenses, and co-develops novel biopharmaceutical compounds originating from Chinese research institutions and pharmaceutical companies for global development and commercialization. The company's portfolio includes clinical-stage compounds in oncology (HBI-8000/Hiyasta, HBI-2376, HBI-2438, HBI-2375, HBI-2448) and cardiovascular (HBI-3000, HBI-3020, HBI-3808), with HBI-8000 approved and marketed in Japan for T-cell lymphomas under the brand Hiyasta.
Is HUYA Bioscience a public or private company?
HUYA Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was HUYA Bioscience founded?
HUYA Bioscience was founded in 2007. It employs 51 to 100 people.
Where is HUYA Bioscience based?
HUYA Bioscience is headquartered in San Diego, United States, in the North America region.
How does HUYA Bioscience make money?
Two revenue lines are on record. Licensing and Co-development Agreements are the primary driver. The others are product Commercialization.
Who are HUYA Bioscience's main competitors?
Direct peers on record are Hutchmed (Chi-Med), BeiGene, Zai Lab, Everest Medicines, LianBio, Cstone Pharmaceuticals, Antengene and I-Mab Biopharma. Emerging players are BridgeBio Pharma and Roivant Sciences.
Does HUYA Bioscience have an API?
No public API is recorded for HUYA Bioscience.
What industry is HUYA Bioscience in?
HUYA Bioscience's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.